Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Alignment with FDA on Registration Path for CRB-701 in 2L HNSCC and Cervical Cancer Announced April 15, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer April 7, 2026
NMPA Accepts New Drug Applications for Toripalimab Subcutaneous Injection Across 12 Indications March 10, 2026
First Interim Analysis in the Global Phase 3 FIERCE-HN Study of ficlatuzumab Completed February 25, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer February 25, 2026
Adoption of Amended Protocol for Ph 3 VERSATILE-003 Trial Incorporating PFS as Primary Endpoint for Interim Analysis and Potential Accelerated Approval Announced February 25, 2026
FDA Alignment on use of PFS as Primary Endpoint in Ph 3 VERSATILE-003 Trial Announced January 11, 2026
BioAtla and GATC Health Announce a $40M SPV Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ OPSCC January 4, 2026
Six-Year JUPITER-02 Follow-up Results Show LOQTORZI® plus Chemo Nearly Doubles Median OS in NPC December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop SC Formulation of Petosemtamab November 24, 2025
FDA Meeting Requested to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer November 4, 2025
EC Approves KEYTRUDA as Part of Treatment Regimen for Adults with Resectable LA-HNSCC Expressing PD-L1 November 4, 2025
First Patient Enrolled in Ph 1 Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 October 21, 2025
Ficerafusp Alfa Granted Breakthrough Therapy Designation by US FDA for 1L HPV-Negative R/M HNSCC October 15, 2025
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 October 7, 2025
Updated Ph 1 Results of JNJ-1900 (NBTXR3) + Anti-PD-1 in 1L/2L+ Anti-PD-1 Naïve or Resistant R/M-HNSCC Announced October 7, 2025
Extended Survival Achieved in Low PD-L1 Cohort in VERSATILE-002 Trial of PDS0101 (Versamune® HPV) + Keytruda in patients with HPV16-positive 1L R/M HNSCC September 23, 2025
Two Positive EU CHMP Opinions for KEYTRUDA, for SC Administration and for New Indication for Earlier-Stage Head and Neck Cancer September 23, 2025
